A number of other analysts have also weighed in on FCSC. Zacks Investment Research lowered shares of Fibrocell Science from a buy rating to a hold rating in a research note on Tuesday, February 6th. HC Wainwright restated a buy rating and set a $6.00 target price on shares of Fibrocell Science in a research note on Tuesday, March 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Fibrocell Science presently has a consensus rating of Hold and an average price target of $4.58.
NASDAQ:FCSC remained flat at $$0.58 on Monday. 27,169 shares of the company’s stock were exchanged, compared to its average volume of 611,913. The stock has a market capitalization of $16.42, a price-to-earnings ratio of -0.35 and a beta of 0.48. Fibrocell Science has a one year low of $0.51 and a one year high of $4.64.
A number of institutional investors have recently made changes to their positions in FCSC. Pura Vida Investments LLC purchased a new position in Fibrocell Science in the third quarter valued at approximately $909,000. FNY Partners Fund LP acquired a new stake in shares of Fibrocell Science during the fourth quarter worth $129,000. Third Security LLC lifted its holdings in shares of Fibrocell Science by 49.2% during the fourth quarter. Third Security LLC now owns 8,267,413 shares of the company’s stock worth $5,292,000 after purchasing an additional 2,727,273 shares during the period. Armistice Capital LLC acquired a new stake in shares of Fibrocell Science during the fourth quarter worth $393,000. Finally, Anson Funds Management LP acquired a new stake in shares of Fibrocell Science during the fourth quarter worth $287,000. Institutional investors own 44.44% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Fibrocell Science (FCSC) Given Buy Rating at Griffin Securities” was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/3335744/fibrocell-science-fcsc-given-buy-rating-at-griffin-securities.html.
About Fibrocell Science
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.